Combine TACE and Autologous Tcm Immunotherapy Versus TACE Alone for HCC With MVI After Radical Resection

Phase 2 Completed 52 enrolled Cancer Institute and Hospital, Chinese Academy of Medical Sciences Newish Technology (Beijing) Co., Ltd. · collab

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the efficacy and safety of combining autologous Tcm immunotherapy and TACE in HCC patients with MVI after radical resection. Patients will be assigned either to the experimental arm to receive autologous Tcm immunotherapy and TACE or to the active comparator (TACE alone).

Timeline

Start: 2017-01-09
Primary completion: 2019-10-31
Completion: 2019-10-31

Publications

Cai J, Zhao J, Liu D, Xie H, Qi H, Ma J, Sun Z, Zhao H. Efficacy and Safety of Central Memory T Cells Combined With Adjuvant Therapy to Prevent Recurrence of Hepatocellular Carcinoma With Microvascular Invasion: A Pilot Study. Front Oncol. 2021 Dec 3;11:781029. doi: 10.3389/fonc.2021.781029. eCollection 2021.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Tcm	Unknown	—	—

Combine TACE and Autologous Tcm Immunotherapy Versus TACE Alone for HCC With MVI After Radical Resection

Summary

Timeline

Publications

Drugs

Indications